AHCL Anlon Healthcare Q3 FY26 results (Oct–Dec 2025) and concall
Anlon Healthcare Limited reported strong Q3 and 9M FY26 results, with significant revenue and profit growth driven by API and intermediate volumes. The company is actively pursuing capacity expansion through greenfield projects and strategic acquisitions (Apiqo Organic, Bizotic Life Science) to support ambitious revenue targets and product diversification. Management is focused on improving working capital efficiency and maintaining healthy EBITDA margins.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 280.1%, net profit up 306.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 24 | 9 | 49 | 33 | 52 +116% | 36 +280% |
| EBITDA | 8 | 1 | 17 | 6 | 14 +83% | 12 +2017% |
| Net profit | 3 | -2 | 17 | 4 | 9 +260% | 5 +307% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
